No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DGX240816P120000
- 0.06
- -0.71-92.21%
15min DelayClose Jul 22 16:00 ET
0.25High0.05Low
0.25Open0.77Pre Close125 Volume181 Open Interest120.00Strike Price2.76KTurnover35.84%IV18.60%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.0120Delta0.0022Gamma2455.83Leverage Ratio-0.0081Theta-0.0010Rho-29.49Eff Leverage0.0121Vega
Intraday
- 5D
- Daily
News
Quest Diagnostics Q2 2024 Earnings Preview
Notable Earnings Before Tuesday's Open
Quest Diagnostics Market Position and Earnings Potential: Analyst Pito Chickering's Outlook Amidst Inflationary Challenges and Growth Strategies
Tesla, AT&T, Alphabet, Chipotle, Visa, and More Stocks to Watch This Week
Second-quarter earnings season continues with Verizon, Alphabet, Coca-Cola, Comcast, General Motors, Tesla, Visa, AT&T, Chipotle, and Newmont.
Labcorp, Quest Among Health Firms to Cite Impact From CrowdStrike Issue
Express News | Quest Diagnostics - Patient Services & Customer Contact Teams Operating With Reduced Capacity, so Customers May Experience Longer Wait & Service Times
Comments
$Quest Diagnostics(DGX.US$ PathAI + Invigorate + stable finance + qualified management team + decent PE.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
Will it dominate pathology and cancer diagnosis with AI in the future? Worth noting.
4
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
The acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Read more